0 Items
Select Page

Legionella

The bacterium L. pneumophila was first identified in 1977, as the cause of an outbreak of severe pneumonia in a convention centre in the USA in 1976. It has since been associated with outbreaks linked to poorly maintained artificial water systems, particularly cooling towers or evaporative condensers associated with air conditioning and industrial cooling, hot and cold water systems in public and private buildings, and whirlpool spas.

 

Our monoclonal antibodies can be used in support of assay development and R&D into Legionella infection.

Legionella background

L. pneumophila is an opportunistic intracellular pathogen that was first recognised in a group of individuals, presenting with a lung infection, who had attended a convention in Philadelphia in 1976. It is the causative agent of a severe type of pneumonia referred to as Legionnaires’ disease. The symptoms of Legionnaires’ disease include shortness of breath, cough, headache, fever and muscle ache, which can occur 2 – 10 days after exposure. Complications associated with infection may result in death. L. pneumophila may also cause a mild form of disease known as Pontiac fever, which is self-limiting and doesn’t require hospitalisation (CDC). Both forms of the disease may also be referred to as Legionellosis.

Legionella Antibodies

We offer a pair of monoclonal antibodies specific for Legionella detection, suitable for use in immunoassay development.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

ELISA Formats for Infectious Disease Diagnostics

The field of diagnostics is rapidly developing, yet ELISA and PCR methods remain the most commonly used techniques in the diagnosis of bacterial and viral infections. In this blog, we discuss the advantages of using serological methods over molecular, PCR-based...

The world’s most extensive range of NS1-specific antibodies for flavivirus research

The Native Antigen Company first gained prominence in 2016, when it developed highly pure Zika virus NS1 protein during the 2015/2016 epidemic. Since then, the company has developed an extensive range of highly specific antigens, antibodies and immunoassays for...

Flavivirus NS1: A Short Introduction

In the first of a two-part series, we describe the structure of Flavivirus Non-Structural Protein 1 (NS1) and the role that it plays in viral pathogenesis. Flavivirus proteins Flaviviruses are single-stranded, enveloped RNA viruses, belonging to the Flaviviridae...

Paper Synopsis: ELISA formats and antibody quenching to reduce ZIKV cross-reactivity

While the 2015/16 Zika epidemic no longer makes the headlines, there remains a crucial need to accurately and reliably diagnose Zika virus (ZIKV) infection to identify and manage further outbreaks. However, high levels of cross-reactivity among cocirculating...

Viral Lysates for Diagnostic Research

We've recently expanded our range of native viral cell lysates to complement our highly pure recombinant antigens. Here, we explain how our lysates are made and their uses in infectious disease R&D.What are viral lysates? Put simply, viral lysates are extracts of...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

14 + 5 =

Live Customer Feedback